Aeglea BioTherapeutics Cultura de la Empresa

Dr. Anthony G. Quinn, M.B Ch.B., Ph.D., FRCP, is a Director of Generation Bio Co. Dr. Quinn has been an Interim Chief Executive Officer of Aeglea Biotherapeutics, Inc. since July 20, 2017. Dr. Quinn served as Interim Chief Medical Officer of Aeglea Biotherapeutics, Inc. from April 21, 2017 to July 10, 2017. Dr. Quinn served as the Chief Medical Officer of Synageva BioPharma Corp. since August 2009 until September 2015 and served as its Executive Vice President from January 2014 to September 2015. Dr. Quinn served as the Senior Vice President and Head of Research & Development at Synageva BioPharma Corp. since August 2009 until January 2014. Dr. Quinn joined Synageva from Roche Palo Alto, LLC where, from September 2004 until joining Synageva, he was Vice President and Global Head of Clinical Research & Exploratory Development for Inflammation Disease Biology. While at Roche, Dr. Quinn managed programs in rheumatology and respiratory indications in exploratory development and biomarker and translational medicine activities in the late clinical and registration phase for MabThera???/Rituxan???, Actemra??? and Ocrelizumab. He joined Roche Palo Alto in 2005 to build the translational medicine and exploratory development capabilities at the site across a broad range of therapeutic areas including CNS, virology and inflammation. Prior to joining Roche, he was Director of Experimental Medicine at AstraZeneca, Charnwood in the UK and he was Professor of Dermatology at Barts & The London School of Medicine, London, England. He has been a Director of Aeglea Biotherapeutics, Inc. since March 15, 2016. He has authored or co-authored more than 50 peer-reviewed journal articles, book chapters, reviews and editorials, predominantly on Hedgehog signaling and the molecular biology of non-melanoma skin cancer. He received his Bachelor of Medical Science with First class honors and his MBChB (M.D.) with commendation from the University of Dundee, UK. Dr. Quinn trained in internal medicine, dermatology and molecular biology at the University of Newcastle upon Tyne and was also awarded his Ph.D. degree there. He completed a postdoctoral fellowship at University of California, San Francisco and is a fellow of the Royal College of Physicians London.

Mr. Charles N. York, II, M.B.A., has been the Chief Financial Officer and Vice President of Aeglea Biotherapeutics, Inc. since September 29, 2015 and its Vice President since September 2015. Mr. York served as Vice President of Finance and Accounting at Aeglea Biotherapeutics, Inc. since July 2014 until September 29, 2015. Mr. York oversees all aspects of finance, accounting, treasury, tax and corporate operations at Aeglea. Mr. York has a proven track record of corporate finance leadership across multiple functions in high-growth start-ups and SEC registered companies. He held Chief Financial Officer and other finance leadership positions in industries which included technology, aerospace, medical devices and pharmaceuticals. Mr. York was instrumental in planning and executing a strategic realignment and capital restructuring of a publicly traded company, which included a debt raise of $10 million on favorable terms and contributed to a positive financial return to equity holders during his tenure. Mr. York is a Certified Public Accountant (CPA) who earned his B.S. in Accounting from the University of Connecticut and his M.B.A. from the McCombs School of Business at the University of Texas at Austin.

Prof. George Georgiou, Ph.D. is the Co-Founder of Aeglea Biotherapeutics, Inc. (formerly Aeglea BioTherapeutics Holdings, LLC) and has been its Director since December 2013. Prof. Georgiou holds the Cockrell Chair in Engineering at the University of Texas at Austin where he serves on the faculties of Chemical Engineering, Biomedical Engineering and Molecular Biosciences. A prolific inventor, Prof. Georgiou holds 27 issued and 46 pending US patents (as well as numerous foreign counterparts) >60% of which, comprising 16 distinct technology suites, have been licensed to pharmaceutical or biotechnology companies. Before co-founding Aeglea, he founded GGMJ, acquired by Maxygen (NASDQ: MAXY) in 2000. Prof. Georgiou was elected member of the National Academy of Engineering (NAE) in 2005 and to the U.S. Institute of Medicine (IOM) of the National Academy of Sciences in 2011. He has received numerous honors for his research and technology accomplishments including being named as one the top ???100 Chemical Engineers of the Modern Era??? by the American Institute of Chemical Engineers. He received his B.Sc. degree in Chemical Engineering from the University of Manchester, U.K. and his M.S. and Ph.D. from Cornell.

Dr. Scott W. Rowlinson, Ph.D. has been Vice President of Research of Aeglea Biotherapeutics, Inc. since February 2014. Dr. Rowlinson has a proven track record of scientific productivity in biologics drug discovery and development and has demonstrated leadership in coordinating drug discovery to clinical development. Dr. Rowlinson has a wealth of experience in the broader concepts of biomolecule drug development, including uncovering factors involved in clinical portfolio attrition and optimal integration of companion diagnostic development and drug development. Dr. Rowlinson was employee at Eli Lilly and Company. Dr. Rowlinson holds a Ph.D. in Physiology and Biochemistry.

Charles York serves as the CFO of Aeglea BioTherapeutics. Charles started at Aeglea BioTherapeutics in Jul of 2014. Charles currently resides in the Austin, Texas Area.

Jim Joffrion serves as the Vice President Clinical Operations of Aeglea BioTherapeutics. Jim started at Aeglea BioTherapeutics in Sep of 2017. Jim currently resides in the Austin, Texas Area.

Leslie Sloan serves as the SVP Operations of Aeglea BioTherapeutics. Leslie started at Aeglea BioTherapeutics in Feb of 2018. Leslie currently resides in the Austin, Texas Area.

Cortney Caudill serves as the Vice President of Manufacturing of Aeglea BioTherapeutics. Cortney started at Aeglea BioTherapeutics in January of 2019. Cortney currently resides in the Austin, Texas Area.

James Wooldridge serves as the Chief Medical Officer of Aeglea BioTherapeutics. James started at Aeglea BioTherapeutics in July of 2017. James currently resides in the Austin, Texas Area.

Susan Alters serves as the Executive Director, Translational Science of Aeglea BioTherapeutics. Susan started at Aeglea BioTherapeutics in November of 2014. Susan currently resides in the San Francisco Bay Area.